首页 > 最新文献

JAMA Network Open最新文献

英文 中文
Naloxone Knowledge, Carrying, Purchase, and Use. 纳洛酮的了解、携带、购买和使用。
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2024.62698
Mireille Jacobson, David Powell

Importance: Widespread naloxone access is a key policy response to the opioid crisis. Naloxone availability is typically estimated from pharmacy sales, which exclude naloxone provided by community organizations, hospitals, and clinics, or sold over-the-counter.

Objective: To estimate naloxone knowledge, carrying, purchase, and use among US adults.

Design, setting, and participants: This survey study included noninstitutionalized adults aged 18 years and older from a national sample and a sample self-reporting opioid dependence. Respondents answered online questions between June 7 and June 29, 2024, about naloxone knowledge, carrying, purchase, and use.

Exposures: Opioid misuse, risk of overdose, risk of overdose by person known to respondent.

Main outcomes and measures: Naloxone knowledge, prevalence of naloxone carrying, purchase, and administration.

Results: The survey included 1515 individuals from a national sample (median [IQR] age, 45 [33-58] years; 770 women [50.8%]; 215 Black [14.2%], 1087 White [71.8%]) and 512 who self-reported opioid dependence. In the national sample, 50 respondents (3.3%) reported opioid dependence, yielding 562 respondents reporting opioid dependence (median [IQR] age, 41 [35-48] years; 404 female [70.2%]; 17 Black [3.0%], 494 White [87.9%]). Overall, 1164 respondents-700 (46.2%) in the national sample and 500 (89.0%) reporting opioid dependence-had heard of naloxone and correctly identified its purpose. One hundred sixty participants (10.6%) in the national sample and 340 participants (60.5%) in the sample reporting opioid dependence reported carrying naloxone. Among those reporting they were "very likely to overdose," 22 respondents (31.0%) in the national sample and 31 (73.8%) with opioid dependence reported carrying naloxone. Among those who know someone very likely to overdose, 43 participants (25.4%) in the national sample and 190 participants (70.1%) reporting opioid dependence reported carrying naloxone. Among those who ever carried naloxone, 108 (42.4%) in the national sample and 97 (22.6%) reporting opioid dependence had ever purchased naloxone. Overall, 128 respondents (8.4%) in the national sample and 267 respondents (47.5%) reporting opioid dependence reported administering naloxone to someone else while 93 (6.1%) in the national sample and 221 (39.3%) reporting opioid dependence reported being administered naloxone.

Conclusions and relevance: In this survey study of naloxone, most respondents reporting opioid dependence correctly identified naloxone's purpose and carried it. Most naloxone carried was not purchased, suggesting a need for new ways, including rapid online surveys, to monitor naloxone possession.

{"title":"Naloxone Knowledge, Carrying, Purchase, and Use.","authors":"Mireille Jacobson, David Powell","doi":"10.1001/jamanetworkopen.2024.62698","DOIUrl":"10.1001/jamanetworkopen.2024.62698","url":null,"abstract":"<p><strong>Importance: </strong>Widespread naloxone access is a key policy response to the opioid crisis. Naloxone availability is typically estimated from pharmacy sales, which exclude naloxone provided by community organizations, hospitals, and clinics, or sold over-the-counter.</p><p><strong>Objective: </strong>To estimate naloxone knowledge, carrying, purchase, and use among US adults.</p><p><strong>Design, setting, and participants: </strong>This survey study included noninstitutionalized adults aged 18 years and older from a national sample and a sample self-reporting opioid dependence. Respondents answered online questions between June 7 and June 29, 2024, about naloxone knowledge, carrying, purchase, and use.</p><p><strong>Exposures: </strong>Opioid misuse, risk of overdose, risk of overdose by person known to respondent.</p><p><strong>Main outcomes and measures: </strong>Naloxone knowledge, prevalence of naloxone carrying, purchase, and administration.</p><p><strong>Results: </strong>The survey included 1515 individuals from a national sample (median [IQR] age, 45 [33-58] years; 770 women [50.8%]; 215 Black [14.2%], 1087 White [71.8%]) and 512 who self-reported opioid dependence. In the national sample, 50 respondents (3.3%) reported opioid dependence, yielding 562 respondents reporting opioid dependence (median [IQR] age, 41 [35-48] years; 404 female [70.2%]; 17 Black [3.0%], 494 White [87.9%]). Overall, 1164 respondents-700 (46.2%) in the national sample and 500 (89.0%) reporting opioid dependence-had heard of naloxone and correctly identified its purpose. One hundred sixty participants (10.6%) in the national sample and 340 participants (60.5%) in the sample reporting opioid dependence reported carrying naloxone. Among those reporting they were \"very likely to overdose,\" 22 respondents (31.0%) in the national sample and 31 (73.8%) with opioid dependence reported carrying naloxone. Among those who know someone very likely to overdose, 43 participants (25.4%) in the national sample and 190 participants (70.1%) reporting opioid dependence reported carrying naloxone. Among those who ever carried naloxone, 108 (42.4%) in the national sample and 97 (22.6%) reporting opioid dependence had ever purchased naloxone. Overall, 128 respondents (8.4%) in the national sample and 267 respondents (47.5%) reporting opioid dependence reported administering naloxone to someone else while 93 (6.1%) in the national sample and 221 (39.3%) reporting opioid dependence reported being administered naloxone.</p><p><strong>Conclusions and relevance: </strong>In this survey study of naloxone, most respondents reporting opioid dependence correctly identified naloxone's purpose and carried it. Most naloxone carried was not purchased, suggesting a need for new ways, including rapid online surveys, to monitor naloxone possession.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e2462698"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual Orientation- and Gender Identity-Affirming Activities Provided in Primary Care.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0392
Ellesse-Roselee L Akre, Ching-Wen Wendy Yang, Greta R Bauer, Matthew Brian Mackwood, A James O'Malley, Elliott S Fisher, Karen E Schifferdecker
<p><strong>Importance: </strong>Addressing health disparities in lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities has been a significant policy focus for more than a decade. Ensuring access to safe, respectful primary health care from knowledgeable clinicians is crucial for reducing health inequalities.</p><p><strong>Objective: </strong>To assess the engagement of primary care practices in LGBTQ+ affirming care activities and identify practice characteristics associated with increased engagement.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study used data from the National Survey of Healthcare Organizations and Systems II, which focused on primary care practices in the US and was administered between June 2022 through February 2023. Participants were primary care physicians and practice managers. Percentages were weighted for national representation. Data were analyzed from November 2023 to December 2024.</p><p><strong>Exposure: </strong>Practice characteristics including practice size, ownership, federally qualified health center (FQHC) designation; percentage of patients enrolled in Medicare; percentage of patients enrolled in Medicaid; having accountable care organization (ACO) contracts for Medicare, Medicaid, or commercial insurance; rurality; census region; and LGBTQ+ Equality Score by state policy.</p><p><strong>Main outcomes and measures: </strong>Sexual orientation- and gender identity- (SOGI) affirming activities, a composite variable reflecting activity specific to SOGI patients.</p><p><strong>Results: </strong>Among 1245 practices in the sample (38.4% response rate), 923 (77.40%) collected data on gender identity, 921 (75.62%) on sexual orientation, and 742 (65.83%) on patients' pronouns. Only 412 practices (34.42%) provided LGBTQ+ training for clinicians and 480 practices (39.20%) provided training for staff. Practices designated as FQHCs had 3.16 (95% CI, 4.60 to 19.73) percentage points higher probability of engaging in all SOGI-affirming activities) compared with non-FQHCs (P = .001). Practices with a Medicaid payer mix at least 50% had 3.28 (95% CI, 1.19 to 5.36) percentage points higher probability than practices with less than 50% Medicaid payer mix (P = .002), and participation in a Medicaid ACO was associated with 4.26 (95% CI, 0.78 to 7.73) percentage points increased probability compared with nonparticipants (P = .02). Each 1-unit increase in the state-level LGBTQ+ Equality Score was associated with 1.07 (95% CI, 0.28 to 1.85) percentage points higher probability of engaging in all SOGI-affirming activities (P = .02). High performance was negatively associated with practice rurality (average marginal effect, -16.00 [95% CI, -29.72 to -2.28]; P = .02), and rural practices were less likely to provide appropriate referrals (average marginal effect, -15.47 [95% CI, -29.22 to -1.72]; P = .03).</p><p><strong>Conclusions and relevance: </strong>These findings suggest there is a
{"title":"Sexual Orientation- and Gender Identity-Affirming Activities Provided in Primary Care.","authors":"Ellesse-Roselee L Akre, Ching-Wen Wendy Yang, Greta R Bauer, Matthew Brian Mackwood, A James O'Malley, Elliott S Fisher, Karen E Schifferdecker","doi":"10.1001/jamanetworkopen.2025.0392","DOIUrl":"10.1001/jamanetworkopen.2025.0392","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Addressing health disparities in lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities has been a significant policy focus for more than a decade. Ensuring access to safe, respectful primary health care from knowledgeable clinicians is crucial for reducing health inequalities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess the engagement of primary care practices in LGBTQ+ affirming care activities and identify practice characteristics associated with increased engagement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study used data from the National Survey of Healthcare Organizations and Systems II, which focused on primary care practices in the US and was administered between June 2022 through February 2023. Participants were primary care physicians and practice managers. Percentages were weighted for national representation. Data were analyzed from November 2023 to December 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Practice characteristics including practice size, ownership, federally qualified health center (FQHC) designation; percentage of patients enrolled in Medicare; percentage of patients enrolled in Medicaid; having accountable care organization (ACO) contracts for Medicare, Medicaid, or commercial insurance; rurality; census region; and LGBTQ+ Equality Score by state policy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Sexual orientation- and gender identity- (SOGI) affirming activities, a composite variable reflecting activity specific to SOGI patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 1245 practices in the sample (38.4% response rate), 923 (77.40%) collected data on gender identity, 921 (75.62%) on sexual orientation, and 742 (65.83%) on patients' pronouns. Only 412 practices (34.42%) provided LGBTQ+ training for clinicians and 480 practices (39.20%) provided training for staff. Practices designated as FQHCs had 3.16 (95% CI, 4.60 to 19.73) percentage points higher probability of engaging in all SOGI-affirming activities) compared with non-FQHCs (P = .001). Practices with a Medicaid payer mix at least 50% had 3.28 (95% CI, 1.19 to 5.36) percentage points higher probability than practices with less than 50% Medicaid payer mix (P = .002), and participation in a Medicaid ACO was associated with 4.26 (95% CI, 0.78 to 7.73) percentage points increased probability compared with nonparticipants (P = .02). Each 1-unit increase in the state-level LGBTQ+ Equality Score was associated with 1.07 (95% CI, 0.28 to 1.85) percentage points higher probability of engaging in all SOGI-affirming activities (P = .02). High performance was negatively associated with practice rurality (average marginal effect, -16.00 [95% CI, -29.72 to -2.28]; P = .02), and rural practices were less likely to provide appropriate referrals (average marginal effect, -15.47 [95% CI, -29.22 to -1.72]; P = .03).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;These findings suggest there is a","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250392"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time From Onset to Diagnosis of Alpha-Gal Syndrome.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2024.61729
Caroline K Maki, Eleanor F Saunders, Marissa L Taylor, Scott P Commins, Lance A Waller, Johanna S Salzer
{"title":"Time From Onset to Diagnosis of Alpha-Gal Syndrome.","authors":"Caroline K Maki, Eleanor F Saunders, Marissa L Taylor, Scott P Commins, Lance A Waller, Johanna S Salzer","doi":"10.1001/jamanetworkopen.2024.61729","DOIUrl":"10.1001/jamanetworkopen.2024.61729","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e2461729"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Figure 3.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.4939
{"title":"Error in Figure 3.","authors":"","doi":"10.1001/jamanetworkopen.2025.4939","DOIUrl":"10.1001/jamanetworkopen.2025.4939","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e254939"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency Care, Hospitalization Rates, and Floods.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0371
Zachary S Wettstein, Canada Parrish, Amber K Sabbatini, Matthew H Rogers, Edmund Seto, Jeremy J Hess

Importance: Flooding is a major environmental hazard, with events increasing in intensity and frequency in the context of climate change. Floods cause significant health and economic impacts, particularly among vulnerable populations, including older adults. However, comprehensive analyses of the health consequences of flooding remain limited.

Objective: To evaluate the morbidity and health care costs among Medicare beneficiaries associated with flood exposure in the US.

Design, setting, and participants: This retrospective cohort study analyzed emergency department (ED) use and unplanned hospitalization among Medicare beneficiaries 65 years or older living in zip code tabulation areas (ZCTAs) that were exposed to large-scale flood events from January 1, 2008, to December 31, 2017. This analysis was conducted from April 3 to December 15, 2023.

Exposure: The primary exposure was the presence of a flood as recorded in the Multisourced Flood Inventories, a spatially distributed flood database.

Main outcomes and measures: A conditional fixed-effects regression approach was used to explore the incidence of all-case and cause-specific ED visits and hospitalizations before and after floods. The primary outcomes measured were the incident rate ratios (IRRs) and associated 95% CIs. Attributable risk percentages and estimated attributable excess visits were calculated. Stratified analyses were performed for evaluation of effect modification. Health care costs associated with these events were measured and standardized to 2017 US dollars.

Results: Among 11 801 527 Medicare beneficiaries 65 years or older (mean [SD] age, 74.4 [7.6] years; 56.3% female), the rate of all-cause ED visits and hospital admissions increased by 4.8% (IRR, 1.05; 95% CI, 1.04-1.05) and 7.4% (IRR, 1.07; 95% CI, 1.07-1.08) after flood exposure, respectively. The mean ZCTA-level cost was $3230 (95% CI, $3198-$3261) per ED visit and $11 310 (95% CI, $11 252-$11 367) for hospitalizations. The national costs to the Medicare system were estimated to be $69 275 429 (95% CI, $63 010 840-$76 315 210) for ED visits and $191 409 579 (95% CI, $172 782 870-$206 181 300) for hospitalizations. Stratified analyses highlighted greater impacts for certain demographic groups, including adults older than 85 years, and specific seasonal patterns.

Conclusions and relevance: In this cohort study of Medicare beneficiaries 65 years or older, flood exposure was associated with increased health care use and costs, underscoring the need for targeted public health strategies and improved disaster preparedness, especially for older adults. These findings contribute to a more comprehensive understanding of the health-related costs of flooding and can be used to inform future climate change resilience and health care planning.

{"title":"Emergency Care, Hospitalization Rates, and Floods.","authors":"Zachary S Wettstein, Canada Parrish, Amber K Sabbatini, Matthew H Rogers, Edmund Seto, Jeremy J Hess","doi":"10.1001/jamanetworkopen.2025.0371","DOIUrl":"10.1001/jamanetworkopen.2025.0371","url":null,"abstract":"<p><strong>Importance: </strong>Flooding is a major environmental hazard, with events increasing in intensity and frequency in the context of climate change. Floods cause significant health and economic impacts, particularly among vulnerable populations, including older adults. However, comprehensive analyses of the health consequences of flooding remain limited.</p><p><strong>Objective: </strong>To evaluate the morbidity and health care costs among Medicare beneficiaries associated with flood exposure in the US.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study analyzed emergency department (ED) use and unplanned hospitalization among Medicare beneficiaries 65 years or older living in zip code tabulation areas (ZCTAs) that were exposed to large-scale flood events from January 1, 2008, to December 31, 2017. This analysis was conducted from April 3 to December 15, 2023.</p><p><strong>Exposure: </strong>The primary exposure was the presence of a flood as recorded in the Multisourced Flood Inventories, a spatially distributed flood database.</p><p><strong>Main outcomes and measures: </strong>A conditional fixed-effects regression approach was used to explore the incidence of all-case and cause-specific ED visits and hospitalizations before and after floods. The primary outcomes measured were the incident rate ratios (IRRs) and associated 95% CIs. Attributable risk percentages and estimated attributable excess visits were calculated. Stratified analyses were performed for evaluation of effect modification. Health care costs associated with these events were measured and standardized to 2017 US dollars.</p><p><strong>Results: </strong>Among 11 801 527 Medicare beneficiaries 65 years or older (mean [SD] age, 74.4 [7.6] years; 56.3% female), the rate of all-cause ED visits and hospital admissions increased by 4.8% (IRR, 1.05; 95% CI, 1.04-1.05) and 7.4% (IRR, 1.07; 95% CI, 1.07-1.08) after flood exposure, respectively. The mean ZCTA-level cost was $3230 (95% CI, $3198-$3261) per ED visit and $11 310 (95% CI, $11 252-$11 367) for hospitalizations. The national costs to the Medicare system were estimated to be $69 275 429 (95% CI, $63 010 840-$76 315 210) for ED visits and $191 409 579 (95% CI, $172 782 870-$206 181 300) for hospitalizations. Stratified analyses highlighted greater impacts for certain demographic groups, including adults older than 85 years, and specific seasonal patterns.</p><p><strong>Conclusions and relevance: </strong>In this cohort study of Medicare beneficiaries 65 years or older, flood exposure was associated with increased health care use and costs, underscoring the need for targeted public health strategies and improved disaster preparedness, especially for older adults. These findings contribute to a more comprehensive understanding of the health-related costs of flooding and can be used to inform future climate change resilience and health care planning.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250371"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Gestational Diabetes to Type 2 Diabetes-Is Poor Sleep to Blame?
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0149
Christian Benedict, Marie-Pierre St-Onge
{"title":"From Gestational Diabetes to Type 2 Diabetes-Is Poor Sleep to Blame?","authors":"Christian Benedict, Marie-Pierre St-Onge","doi":"10.1001/jamanetworkopen.2025.0149","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.0149","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250149"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Pembrolizumab With Chemoradiotherapy for Locally Advanced Cervical Cancer.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0033
P Travis Courtney, Puja S Venkat, Ya-Chen Tina Shih, Albert J Chang, Alan Lee, Michael L Steinberg, Ann C Raldow

Importance: The KEYNOTE-A18 trial demonstrated that adding concurrent and adjuvant pembrolizumab to chemoradiotherapy and brachytherapy significantly improved survival in patients with newly diagnosed, locally advanced cervical cancer. However, considering the annual global incidence of 660 000 cases of cervical cancer, including 13 820 in the US in 2024, incorporating this regimen into the standard of care could have substantial health care economic implications for both patients and the health care system.

Objective: To determine the cost-effectiveness of adding pembrolizumab to the first-line treatment of newly diagnosed, locally advanced cervical cancer.

Design, setting, and participants: This economic evaluation created a Markov model simulating 50-year outcomes to evaluate cost-effectiveness from the payer perspective for patients receiving either pembrolizumab or placebo in addition to chemoradiotherapy plus brachytherapy. Probabilities, including disease progression, survival, and treatment-related toxic effects, were derived from KEYNOTE-A18 clinical trial data in patients with newly diagnosed, locally advanced cervical cancer. Costs and health utilities were obtained from published literature; 1-way, 3-way, and probabilistic sensitivity analyses were used to assess model uncertainty. Data analyses were conducted from April to November 2024.

Exposure: Pembrolizumab.

Main outcomes and measures: Costs, measured in 2024 US dollars, and effectiveness, measured in quality-adjusted life-years (QALYs) were used to calculate an incremental cost-effectiveness ratio (ICER). A willingness-to-pay threshold of $100 000 per QALY was chosen, below which pembrolizumab would be considered cost-effective.

Results: KEYNOTE-A18 enrolled 1060 patients (529 in pembrolizumab group, 531 in placebo group). The median age was 50 years. Pembrolizumab increased costs by $257 000 and effectiveness by 1.40 QALYs, yielding an incremental cost-effectiveness ratio of $183 400 per QALY. The addition of pembrolizumab became cost-effective if its monthly cost was decreased from $16 990 to $9190 (a 45.6% reduction) or its maximum duration of 24 months was decreased to 10 months. The model was insensitive to assumptions about treatment-related toxic effects, progression-free survival, and overall survival. Probabilistic sensitivity analysis indicated that at a willingness-to-pay threshold of $100 000 per QALY, the addition of pembrolizumab was cost-effective 37.3% of the time.

Conclusions and relevance: In this economic evaluation of adding concurrent and adjuvant pembrolizumab to first-line treatment of newly diagnosed, locally advanced cervical cancer, this regimen was not cost-effective at current prices despite data demonstrating improved survival with this regimen.

{"title":"Cost-Effectiveness of Pembrolizumab With Chemoradiotherapy for Locally Advanced Cervical Cancer.","authors":"P Travis Courtney, Puja S Venkat, Ya-Chen Tina Shih, Albert J Chang, Alan Lee, Michael L Steinberg, Ann C Raldow","doi":"10.1001/jamanetworkopen.2025.0033","DOIUrl":"10.1001/jamanetworkopen.2025.0033","url":null,"abstract":"<p><strong>Importance: </strong>The KEYNOTE-A18 trial demonstrated that adding concurrent and adjuvant pembrolizumab to chemoradiotherapy and brachytherapy significantly improved survival in patients with newly diagnosed, locally advanced cervical cancer. However, considering the annual global incidence of 660 000 cases of cervical cancer, including 13 820 in the US in 2024, incorporating this regimen into the standard of care could have substantial health care economic implications for both patients and the health care system.</p><p><strong>Objective: </strong>To determine the cost-effectiveness of adding pembrolizumab to the first-line treatment of newly diagnosed, locally advanced cervical cancer.</p><p><strong>Design, setting, and participants: </strong>This economic evaluation created a Markov model simulating 50-year outcomes to evaluate cost-effectiveness from the payer perspective for patients receiving either pembrolizumab or placebo in addition to chemoradiotherapy plus brachytherapy. Probabilities, including disease progression, survival, and treatment-related toxic effects, were derived from KEYNOTE-A18 clinical trial data in patients with newly diagnosed, locally advanced cervical cancer. Costs and health utilities were obtained from published literature; 1-way, 3-way, and probabilistic sensitivity analyses were used to assess model uncertainty. Data analyses were conducted from April to November 2024.</p><p><strong>Exposure: </strong>Pembrolizumab.</p><p><strong>Main outcomes and measures: </strong>Costs, measured in 2024 US dollars, and effectiveness, measured in quality-adjusted life-years (QALYs) were used to calculate an incremental cost-effectiveness ratio (ICER). A willingness-to-pay threshold of $100 000 per QALY was chosen, below which pembrolizumab would be considered cost-effective.</p><p><strong>Results: </strong>KEYNOTE-A18 enrolled 1060 patients (529 in pembrolizumab group, 531 in placebo group). The median age was 50 years. Pembrolizumab increased costs by $257 000 and effectiveness by 1.40 QALYs, yielding an incremental cost-effectiveness ratio of $183 400 per QALY. The addition of pembrolizumab became cost-effective if its monthly cost was decreased from $16 990 to $9190 (a 45.6% reduction) or its maximum duration of 24 months was decreased to 10 months. The model was insensitive to assumptions about treatment-related toxic effects, progression-free survival, and overall survival. Probabilistic sensitivity analysis indicated that at a willingness-to-pay threshold of $100 000 per QALY, the addition of pembrolizumab was cost-effective 37.3% of the time.</p><p><strong>Conclusions and relevance: </strong>In this economic evaluation of adding concurrent and adjuvant pembrolizumab to first-line treatment of newly diagnosed, locally advanced cervical cancer, this regimen was not cost-effective at current prices despite data demonstrating improved survival with this regimen.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250033"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Veterans at High Risk for Post-COVID-19 Suicide Attempts or Other Self-Directed Violence.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0061
David P Bui, Meike Niederhausen, Alex W Hickok, Diana J Govier, Mazhgan Rowneki, Jennifer C Naylor, Eric Hawkins, Edward J Boyko, Theodore J Iwashyna, Elizabeth M Viglianti, George N Ioannou, Jason I Chen, Denise M Hynes

Importance: US veterans have a higher risk of suicide than the general civilian population. Research suggests that COVID-19 infection is associated with increased risk of suicide attempts or other forms of self-directed violence (SDV) among veterans.

Objective: To identify subgroups of veterans with high risk of post-COVID-19 suicide attempts or SDV.

Design, setting, and participants: This is a retrospective cohort study conducted using data from the Veteran Health Administration (VHA). Participants included VHA enrollees with a first case of COVID-19 between May 1, 2021, and April 30, 2022, residing in the 50 states or Washington, DC.

Exposure: COVID-19 infection.

Main outcomes and measures: The main outcome was a suicide attempt or SDV 12 months after COVID-19 infection. Latent class analysis was used to identify subgroups. Outcome rates and 95% CIs per 10 000 veterans were calculated. Multinomial regressions were used to model outcome risk and marginal risk ratios with 99.5% CIs to compare outcome risk across latent classes.

Results: The cohort included 285 235 veterans with COVID-19 and was predominantly male (248 118 veterans [87.0%]) and younger than 65 years (171 636 veterans [60.2%]). Chronic pain (152 788 veterans [53.6%]), depression (98 093 veterans [34.4%]), and posttraumatic stress disorder (79 462 veterans [27.9%]) diagnoses were common. The 12-month outcome rate was 73.8 events per 10 000 (95% CI, 70.7-77.0 events per 10 000). Two latent classes with high rates of suicide attempt or SDV were identified. The first high-risk subgroup (46 693 veterans [16.4%]) was older (34 472 veterans [73.8%] aged ≥65 years) and had a high prevalence of physical conditions (43 329 veterans [92.8%] had hypertension, and 36 824 veterans [78.9%] had chronic pain); the 12-month outcome rate was 103.7 events per 10 000 (95% CI, 94.7-113.3 events per 10 000). The second high-risk subgroup (82 309 veterans [28.9%]) was generally younger (68 822 veterans [83.6%] aged <65 years) with a lower prevalence of physical conditions but high prevalence of mental health conditions (61 367 veterans [74.6%] had depression, and 50 073 veterans [60.8%] had posttraumatic stress disorder); the 12-month outcome rate was 162.9 events per 10 000 (95% CI, 154.5-171.8 events per 10 000), and compared with the lowest risk subgroup, the 12-month risk of suicide attempts or SDV was 14 times higher in this subgroup (risk ratio, 14.23; 99.5% CI, 10.22-19.80).

Conclusions and relevance: In this cohort study of veterans with COVID-19, 2 veteran subgroups with distinct health profiles had high rates of suicide attempts and SDV, suggesting that different groups may require different approaches to suicide prevention after COVID-19.

{"title":"Veterans at High Risk for Post-COVID-19 Suicide Attempts or Other Self-Directed Violence.","authors":"David P Bui, Meike Niederhausen, Alex W Hickok, Diana J Govier, Mazhgan Rowneki, Jennifer C Naylor, Eric Hawkins, Edward J Boyko, Theodore J Iwashyna, Elizabeth M Viglianti, George N Ioannou, Jason I Chen, Denise M Hynes","doi":"10.1001/jamanetworkopen.2025.0061","DOIUrl":"10.1001/jamanetworkopen.2025.0061","url":null,"abstract":"<p><strong>Importance: </strong>US veterans have a higher risk of suicide than the general civilian population. Research suggests that COVID-19 infection is associated with increased risk of suicide attempts or other forms of self-directed violence (SDV) among veterans.</p><p><strong>Objective: </strong>To identify subgroups of veterans with high risk of post-COVID-19 suicide attempts or SDV.</p><p><strong>Design, setting, and participants: </strong>This is a retrospective cohort study conducted using data from the Veteran Health Administration (VHA). Participants included VHA enrollees with a first case of COVID-19 between May 1, 2021, and April 30, 2022, residing in the 50 states or Washington, DC.</p><p><strong>Exposure: </strong>COVID-19 infection.</p><p><strong>Main outcomes and measures: </strong>The main outcome was a suicide attempt or SDV 12 months after COVID-19 infection. Latent class analysis was used to identify subgroups. Outcome rates and 95% CIs per 10 000 veterans were calculated. Multinomial regressions were used to model outcome risk and marginal risk ratios with 99.5% CIs to compare outcome risk across latent classes.</p><p><strong>Results: </strong>The cohort included 285 235 veterans with COVID-19 and was predominantly male (248 118 veterans [87.0%]) and younger than 65 years (171 636 veterans [60.2%]). Chronic pain (152 788 veterans [53.6%]), depression (98 093 veterans [34.4%]), and posttraumatic stress disorder (79 462 veterans [27.9%]) diagnoses were common. The 12-month outcome rate was 73.8 events per 10 000 (95% CI, 70.7-77.0 events per 10 000). Two latent classes with high rates of suicide attempt or SDV were identified. The first high-risk subgroup (46 693 veterans [16.4%]) was older (34 472 veterans [73.8%] aged ≥65 years) and had a high prevalence of physical conditions (43 329 veterans [92.8%] had hypertension, and 36 824 veterans [78.9%] had chronic pain); the 12-month outcome rate was 103.7 events per 10 000 (95% CI, 94.7-113.3 events per 10 000). The second high-risk subgroup (82 309 veterans [28.9%]) was generally younger (68 822 veterans [83.6%] aged <65 years) with a lower prevalence of physical conditions but high prevalence of mental health conditions (61 367 veterans [74.6%] had depression, and 50 073 veterans [60.8%] had posttraumatic stress disorder); the 12-month outcome rate was 162.9 events per 10 000 (95% CI, 154.5-171.8 events per 10 000), and compared with the lowest risk subgroup, the 12-month risk of suicide attempts or SDV was 14 times higher in this subgroup (risk ratio, 14.23; 99.5% CI, 10.22-19.80).</p><p><strong>Conclusions and relevance: </strong>In this cohort study of veterans with COVID-19, 2 veteran subgroups with distinct health profiles had high rates of suicide attempts and SDV, suggesting that different groups may require different approaches to suicide prevention after COVID-19.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250061"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Embolism in Patients with End-Stage Kidney Disease Starting Dialysis.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0848
Kunal N Patel, Wan-Chi Chan, Vivek Bhat, Monil M Majmundar, Harsh Mehta, Cyrus Munguti, Kartik Munshi, Sri G Yarlagadda, Gaurav M Parmar, Aditya M Sharma, Daniella Kadian-Dodov, Lewis G Satterwhite, Jinxiang Hu, Jordan Baker Ms, Kamal Gupta
{"title":"Pulmonary Embolism in Patients with End-Stage Kidney Disease Starting Dialysis.","authors":"Kunal N Patel, Wan-Chi Chan, Vivek Bhat, Monil M Majmundar, Harsh Mehta, Cyrus Munguti, Kartik Munshi, Sri G Yarlagadda, Gaurav M Parmar, Aditya M Sharma, Daniella Kadian-Dodov, Lewis G Satterwhite, Jinxiang Hu, Jordan Baker Ms, Kamal Gupta","doi":"10.1001/jamanetworkopen.2025.0848","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.0848","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250848"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. 医疗补助管理性保健计划中的酒精使用障碍用药范围和使用管理。
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0695
Maureen T Stewart, Sage R Feltus, Christina M Andrews, Andrea Acevedo, Cindy Parks Thomas, Jeffrey Bratberg, Constance M Horgan, Dominic Hodgkin, Rachel Sayko Adams

Importance: Evidence-based, patient-centered treatment for alcohol use disorder (AUD) can include pharmacotherapy with naltrexone, acamprosate, or disulfiram; however, these medications are rarely used. Medicaid managed care plans (MCPs) manage health services for nearly 80% of Medicaid enrollees and are the largest payer for addiction treatment services. Little is known about Medicaid MCP policies for AUD medications.

Objectives: To describe Medicaid MCPs' coverage and management of acamprosate, naltrexone, and disulfiram for AUD and examine associations of plan characteristics and state policies with medication coverage.

Design, setting, and participants: In this cross-sectional study, a content analysis was performed of 2021 insurance benefit data for 241 comprehensive Medicaid MCPs in states using Medicaid managed care, as well as secondary sources. Data were analyzed from May to August 2024.

Main outcomes and measures: Medicaid MCP-reported medication coverage and utilization management requirements (eg, prior authorization, quantity limit requirements) for acamprosate, disulfiram, and oral and injectable naltrexone together and for each medication separately. Independent variables included plan characteristics (profit status, market share) and the state policy environment in which plans are embedded (Section 1115 substance use disorder waiver, state-defined preferred drug list). Regressions examined associations of plan characteristics and state policies with medication coverage.

Results: In this cross-sectional content analysis of 241 comprehensive Medicaid MCPs in 2021, 217 (90.0%) covered at least 1 medication for AUD: 132 (54.7%) covered acamprosate, 203 (84.2%) covered oral naltrexone, 175 (72.6%) covered injectable naltrexone, 152 (63.0%) covered disulfiram, and 103 (42.7%) covered all 4 medications. Prior authorization and quantity limits were rarely applied, except for injectable naltrexone, for which 75 plans (42.8%) imposed at least 1 of these utilization management requirements.

Conclusions and relevance: This study suggests that efforts to expand AUD medication prescribing may be limited by gaps in health insurance coverage. Medicaid MCPs and states can support AUD medication utilization by covering these medications without applying utilization management strategies.

{"title":"Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans.","authors":"Maureen T Stewart, Sage R Feltus, Christina M Andrews, Andrea Acevedo, Cindy Parks Thomas, Jeffrey Bratberg, Constance M Horgan, Dominic Hodgkin, Rachel Sayko Adams","doi":"10.1001/jamanetworkopen.2025.0695","DOIUrl":"10.1001/jamanetworkopen.2025.0695","url":null,"abstract":"<p><strong>Importance: </strong>Evidence-based, patient-centered treatment for alcohol use disorder (AUD) can include pharmacotherapy with naltrexone, acamprosate, or disulfiram; however, these medications are rarely used. Medicaid managed care plans (MCPs) manage health services for nearly 80% of Medicaid enrollees and are the largest payer for addiction treatment services. Little is known about Medicaid MCP policies for AUD medications.</p><p><strong>Objectives: </strong>To describe Medicaid MCPs' coverage and management of acamprosate, naltrexone, and disulfiram for AUD and examine associations of plan characteristics and state policies with medication coverage.</p><p><strong>Design, setting, and participants: </strong>In this cross-sectional study, a content analysis was performed of 2021 insurance benefit data for 241 comprehensive Medicaid MCPs in states using Medicaid managed care, as well as secondary sources. Data were analyzed from May to August 2024.</p><p><strong>Main outcomes and measures: </strong>Medicaid MCP-reported medication coverage and utilization management requirements (eg, prior authorization, quantity limit requirements) for acamprosate, disulfiram, and oral and injectable naltrexone together and for each medication separately. Independent variables included plan characteristics (profit status, market share) and the state policy environment in which plans are embedded (Section 1115 substance use disorder waiver, state-defined preferred drug list). Regressions examined associations of plan characteristics and state policies with medication coverage.</p><p><strong>Results: </strong>In this cross-sectional content analysis of 241 comprehensive Medicaid MCPs in 2021, 217 (90.0%) covered at least 1 medication for AUD: 132 (54.7%) covered acamprosate, 203 (84.2%) covered oral naltrexone, 175 (72.6%) covered injectable naltrexone, 152 (63.0%) covered disulfiram, and 103 (42.7%) covered all 4 medications. Prior authorization and quantity limits were rarely applied, except for injectable naltrexone, for which 75 plans (42.8%) imposed at least 1 of these utilization management requirements.</p><p><strong>Conclusions and relevance: </strong>This study suggests that efforts to expand AUD medication prescribing may be limited by gaps in health insurance coverage. Medicaid MCPs and states can support AUD medication utilization by covering these medications without applying utilization management strategies.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250695"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Network Open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1